CoDa Therapeutics Inc., of San Diego, reported Phase IIb data showing that Nexagon in patients with chronic venous leg ulcers was found to be safe and produced an increase in complete healing in the vehicle-controlled trial

Orexigen Therapeutics Inc., of San Diego, disclosed progress with the FDA on a faster path to resubmission for a new drug application (NDA) for obesity candidate Contrave (naltrexone SR/bupropion SR

Receptos Inc., of San Diego, dosed the first patient in a Phase II study of its selective sphingosine‐1‐ phosphate 1 receptor modulator, RPC1063, in moderately to severely active ulcerative colitis

Zogenix Inc., of San Diego, reported single-dose pharmacokinetic results from a Phase I trial testing Relday, a once-monthly subcutaneous formulation of risperidone for treating schizophrenia, showing that adverse events were generally mild to moderate and consistent with other risperidone products

Adventrx Pharmaceuticals Inc., of San Diego, said ANX-188 (purified poloxamer 188) passed quality control release specifications and is in the quality assurance release process for a Phase III study in sickle cell disease...Neurocrine Biosciences Inc., of San Diego, said it started a Phase IIb trial (Kinect 2 Study) of its vesicular monoamine transporter 2 compound, NBI-98854

Orexigen Therapeutics Inc., of San Diego, provided an update on its cardiovascular outcomes trial for obesity candidate Contrave (naltrexone SR/bupropion

Celladon Corp., of San Diego, dosed its first patient in Europe in a Phase IIb trial of Mydicar for heart failure

Ligand Pharmaceuticals Inc., of San Diego, started a pivotal trial with Captisol-enabled, propylene glycol-free (PG-free) high-dose melphalan as a conditioning treatment prior to autologous transplant for patients with multiple myeloma

Trius Therapeutics Inc., of San Diego, said it reached its enrollment objective of 658 patients in the last of its two Phase III trials of tedizolid phosphate (TR-701) for the treatment of acute bacterial skin and skin structure infections

The data were presented the DNA Vaccines 2012 conference in San Diego

BrainCells Inc., of San Diego, said it completed a Phase I multiple-ascending-dose study of BCI-838, an oral prodrug of the company's Group II mGluR2/3 antagonist, BCI-632

Those and other data were presented at the American Epilepsy Society meeting in San Diego

Upsher-Smith Laboratories Inc., of San Diego, said Phase I data showing that USL261 (intranasal midazolam) demonstrated that maximum midazolam plasma concentrations were rapidly achieved after dosing, and both midazolam and its metabolite were rapidly eliminated...Data were presented at the American Epilepsy Society meeting in San Diego

Fate Therapeutics Inc., of San Diego, initiated a Phase II study of its hematopoietic stem cell therapy, ProHema, in adult patients undergoing double umbilical cord blood transplantation for hematologic malignancy

MediciNova Inc., of San Diego, started enrolling a Phase IIa trial testing MN-166 (ibudilast) in prescription opioid or heroin abusers

OncoSec Medical Inc., of San Diego, reported that ImmunoPulse, delivered by electroporation, may give increased levels of interleukin-12 in the microenvironment of tumors in Merkel cell carcinoma

OncoSec Medical Inc., of San Diego, reported interim results from a Phase IV trial of NeoPulse in skin cancer at the World Meeting of Interdisciplinary Melanoma and Skin Care Centres and EADO Congress in Barcelona, Spain, showing a complete response greater than 90 percent in basal cell carcinoma patients and 70 percent in squamous cell carcinoma patients at six months

MediciNova Inc., of San Diego, said Phase II results published in the Journal of Asthma demonstrated the safety, tolerability and FEV1 improvements in mild-moderate and moderate to severe asthmatics treated with MN-221 (bedoradrine), a selective beta(2)-adrenergic receptor agonist...Santarus Inc., of San Diego, and VeroScience LLC, of Tiverton, R.I., reported new analyses of cardiovascular endpoint data from a previously disclosed 52-week study with Cycloset (bromocriptine), showing that the quick

Ocera Therapeutics Inc., of San Diego, said the first patient was enrolled in a Phase IIa study to test OCR-002 (ornithine phenylacetate) in acute liver injury, as well as in patients who have progressed to acute liver failure following acetaminophen overdose